Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m)

Research output: Contribution to journalArticlepeer-review

Standard

Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m). / Lucas, Samuel J. E.; Malein, William L; Thomas, Owen D; Ashdown, Kimberly M; Rue, Carla A; Joyce, Kelsey E.; Newman, Charles; Cadigan, Patrick; Johnson, Brian; Myers, Stephen D; Myers, Fiona A; Wright, Alexander D.; Delamere, John; Imray, Chris H E; Bradwell, Arthur R.; Edsell, Mark.

In: BMJ Open Sport & Exercise Medicine, Vol. 7, No. 1, e000982, 07.01.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

Lucas, SJE, Malein, WL, Thomas, OD, Ashdown, KM, Rue, CA, Joyce, KE, Newman, C, Cadigan, P, Johnson, B, Myers, SD, Myers, FA, Wright, AD, Delamere, J, Imray, CHE, Bradwell, AR & Edsell, M 2021, 'Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m)', BMJ Open Sport & Exercise Medicine, vol. 7, no. 1, e000982. https://doi.org/10.1136/bmjsem-2020-000982

APA

Lucas, S. J. E., Malein, W. L., Thomas, O. D., Ashdown, K. M., Rue, C. A., Joyce, K. E., Newman, C., Cadigan, P., Johnson, B., Myers, S. D., Myers, F. A., Wright, A. D., Delamere, J., Imray, C. H. E., Bradwell, A. R., & Edsell, M. (2021). Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m). BMJ Open Sport & Exercise Medicine, 7(1), [e000982]. https://doi.org/10.1136/bmjsem-2020-000982

Vancouver

Author

Lucas, Samuel J. E. ; Malein, William L ; Thomas, Owen D ; Ashdown, Kimberly M ; Rue, Carla A ; Joyce, Kelsey E. ; Newman, Charles ; Cadigan, Patrick ; Johnson, Brian ; Myers, Stephen D ; Myers, Fiona A ; Wright, Alexander D. ; Delamere, John ; Imray, Chris H E ; Bradwell, Arthur R. ; Edsell, Mark. / Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m). In: BMJ Open Sport & Exercise Medicine. 2021 ; Vol. 7, No. 1.

Bibtex

@article{adc1169c39f346da82db7baaec7faa87,
title = "Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m)",
abstract = "Objective Altitude-related and exercise-related elevations in blood pressure (BP) increase the likelihood of developing pulmonary hypertension and high-Altitude illness during high-Altitude sojourn. This study examined the antihypertensive effect and potential exercise benefit of the angiotensin II receptor antagonist losartan when taken at altitude. Methods Twenty participants, paired for age and ACE genotype status, completed a double-blinded, randomised study, where participants took either losartan (100 mg/day) or placebo for 21 days prior to arrival at 5035 m (Whymper Hut, Mt Chimborazo, Ecuador). Participants completed a maximal exercise test on a supine cycle ergometer at sea level (4 weeks prior) and within 48 hours of arrival to 5035 m (10-day ascent). Power output, beat-To-beat BP, oxygen saturation (SpO 2) and heart rate (HR) were recorded during exercise, with resting BP collected from daily medicals during ascent. Before and immediately following exercise at 5035 m, extravascular lung water prevalence was assessed with ultrasound (quantified via B-line count). Results At altitude, peak power was reduced relative to sea level (p<0.01) in both groups (losartan vs placebo: down 100±29 vs 91±28 W, p=0.55), while SpO 2 (70±6 vs 70±5%, p=0.96) and HR (146±21 vs 149±24 bpm, p=0.78) were similar between groups at peak power, as was the increase in systolic BP from rest to peak power (up 80±37 vs 69±33 mm Hg, p=0.56). Exercise increased B-line count (p<0.05), but not differently between groups (up 5±5 vs 8±10, p=0.44). Conclusion Losartan had no observable effect on resting or exercising BP, exercise-induced symptomology of pulmonary hypertension or performance at 5035 m.",
keywords = "altitude, cardiovascular, exercise, pulmonary",
author = "Lucas, {Samuel J. E.} and Malein, {William L} and Thomas, {Owen D} and Ashdown, {Kimberly M} and Rue, {Carla A} and Joyce, {Kelsey E.} and Charles Newman and Patrick Cadigan and Brian Johnson and Myers, {Stephen D} and Myers, {Fiona A} and Wright, {Alexander D.} and John Delamere and Imray, {Chris H E} and Bradwell, {Arthur R.} and Mark Edsell",
note = "Funding Information: This study was supported by the Birmingham Medical Research Expeditionary Society, which provided input for the conduct of the research. Patients were not included. Public involvement was limited to recruitment. Notification was given to participants at the time of consent that acquisition of personal data was permitted on request. Permission was also obtained at this time for the dissemination of deidentified data within the research team and only externally when a reasonable request was submitted directly to the corresponding author of the present study within 6 months of its publication. A portion of the cohort was invited to review the research methods for accuracy and readability. Funding Information: Funding This study was supported by a grant from the JABBS Foundation. Competing interests None declared. Patient consent for publication Not required. ",
year = "2021",
month = jan,
day = "7",
doi = "10.1136/bmjsem-2020-000982",
language = "English",
volume = "7",
journal = "BMJ Open Sport & Exercise Medicine",
issn = "2055-7647",
publisher = "BMJ Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m)

AU - Lucas, Samuel J. E.

AU - Malein, William L

AU - Thomas, Owen D

AU - Ashdown, Kimberly M

AU - Rue, Carla A

AU - Joyce, Kelsey E.

AU - Newman, Charles

AU - Cadigan, Patrick

AU - Johnson, Brian

AU - Myers, Stephen D

AU - Myers, Fiona A

AU - Wright, Alexander D.

AU - Delamere, John

AU - Imray, Chris H E

AU - Bradwell, Arthur R.

AU - Edsell, Mark

N1 - Funding Information: This study was supported by the Birmingham Medical Research Expeditionary Society, which provided input for the conduct of the research. Patients were not included. Public involvement was limited to recruitment. Notification was given to participants at the time of consent that acquisition of personal data was permitted on request. Permission was also obtained at this time for the dissemination of deidentified data within the research team and only externally when a reasonable request was submitted directly to the corresponding author of the present study within 6 months of its publication. A portion of the cohort was invited to review the research methods for accuracy and readability. Funding Information: Funding This study was supported by a grant from the JABBS Foundation. Competing interests None declared. Patient consent for publication Not required.

PY - 2021/1/7

Y1 - 2021/1/7

N2 - Objective Altitude-related and exercise-related elevations in blood pressure (BP) increase the likelihood of developing pulmonary hypertension and high-Altitude illness during high-Altitude sojourn. This study examined the antihypertensive effect and potential exercise benefit of the angiotensin II receptor antagonist losartan when taken at altitude. Methods Twenty participants, paired for age and ACE genotype status, completed a double-blinded, randomised study, where participants took either losartan (100 mg/day) or placebo for 21 days prior to arrival at 5035 m (Whymper Hut, Mt Chimborazo, Ecuador). Participants completed a maximal exercise test on a supine cycle ergometer at sea level (4 weeks prior) and within 48 hours of arrival to 5035 m (10-day ascent). Power output, beat-To-beat BP, oxygen saturation (SpO 2) and heart rate (HR) were recorded during exercise, with resting BP collected from daily medicals during ascent. Before and immediately following exercise at 5035 m, extravascular lung water prevalence was assessed with ultrasound (quantified via B-line count). Results At altitude, peak power was reduced relative to sea level (p<0.01) in both groups (losartan vs placebo: down 100±29 vs 91±28 W, p=0.55), while SpO 2 (70±6 vs 70±5%, p=0.96) and HR (146±21 vs 149±24 bpm, p=0.78) were similar between groups at peak power, as was the increase in systolic BP from rest to peak power (up 80±37 vs 69±33 mm Hg, p=0.56). Exercise increased B-line count (p<0.05), but not differently between groups (up 5±5 vs 8±10, p=0.44). Conclusion Losartan had no observable effect on resting or exercising BP, exercise-induced symptomology of pulmonary hypertension or performance at 5035 m.

AB - Objective Altitude-related and exercise-related elevations in blood pressure (BP) increase the likelihood of developing pulmonary hypertension and high-Altitude illness during high-Altitude sojourn. This study examined the antihypertensive effect and potential exercise benefit of the angiotensin II receptor antagonist losartan when taken at altitude. Methods Twenty participants, paired for age and ACE genotype status, completed a double-blinded, randomised study, where participants took either losartan (100 mg/day) or placebo for 21 days prior to arrival at 5035 m (Whymper Hut, Mt Chimborazo, Ecuador). Participants completed a maximal exercise test on a supine cycle ergometer at sea level (4 weeks prior) and within 48 hours of arrival to 5035 m (10-day ascent). Power output, beat-To-beat BP, oxygen saturation (SpO 2) and heart rate (HR) were recorded during exercise, with resting BP collected from daily medicals during ascent. Before and immediately following exercise at 5035 m, extravascular lung water prevalence was assessed with ultrasound (quantified via B-line count). Results At altitude, peak power was reduced relative to sea level (p<0.01) in both groups (losartan vs placebo: down 100±29 vs 91±28 W, p=0.55), while SpO 2 (70±6 vs 70±5%, p=0.96) and HR (146±21 vs 149±24 bpm, p=0.78) were similar between groups at peak power, as was the increase in systolic BP from rest to peak power (up 80±37 vs 69±33 mm Hg, p=0.56). Exercise increased B-line count (p<0.05), but not differently between groups (up 5±5 vs 8±10, p=0.44). Conclusion Losartan had no observable effect on resting or exercising BP, exercise-induced symptomology of pulmonary hypertension or performance at 5035 m.

KW - altitude

KW - cardiovascular

KW - exercise

KW - pulmonary

UR - http://www.scopus.com/inward/record.url?scp=85099141906&partnerID=8YFLogxK

U2 - 10.1136/bmjsem-2020-000982

DO - 10.1136/bmjsem-2020-000982

M3 - Article

C2 - 33489310

VL - 7

JO - BMJ Open Sport & Exercise Medicine

JF - BMJ Open Sport & Exercise Medicine

SN - 2055-7647

IS - 1

M1 - e000982

ER -